Abstract:BACKGROUND: Delirium is an acute organic brain syndrome caused by various reasons, and it is common in elderly patients. Antipsychotics treatment is an important method to control delirium.OBJECTIVE: To observe the efficacy of new antipsychotic agent of olanzapine and the traditional antipsychotic agent of haloperidol in treating senile delirium.DESIGN: A randomized controlled observation. SETTING: Mental Health Center, the First Affiliated Hospital of Chongqing University of Medical Sciences.PARTICIPANTS: Totally 175 inpatients with senile delirium were selected from the First Affiliated Hospital of Chongqing University of Medical Sciences from September 2001 to September 2003, they were randomly divided into olanzapine treatment group (n=74), haloperidol treatment group (n=72) and a control group(n=29). There were 111 males (63.4%) and 64 females (36.6%). Delirium had occurred for a duration of 30 minutes to 17 days, with an average of (3.02±2.71) days. The enrolled patients were classified according to the etiological factors of delirium: metabolic (n=68), toxic (n=47), structural (n=25) and infectious (n=35).METHODS: Different treatments were used in different groups. Control group (n=29): The patients were only given somatic treatment aiming at delirium, and not any drug for central nervous system was used. Olanzapine group (n=74): Besides the somatic treatment aiming at delirium, the patients were given olanzapine (Zyprexa, produced by Eli Lilly and Company,5 mg/tablet) taken orally or sublingually (fasted patients), the initial dosage was 1.25-2.5 mg per day, and then adjusted to 1.25-20 mg per day. Haloperidol group (n=72): Besides the somatic treatment aiming at delirium, they were treated with intramuscular injection of haloperidol (2.5-10 mg per day). The effects were prospectively observed for 1 week.The scores were observed before enrollment and at 1-7 days respectively,the severity of mental disorder and amelioration were evaluated by the clinical global impression scale-severity of illness (CGI-SI) and global improvement item of clinical global impression scale (CGI-GI). The dosage and time of administration was taken as the dosage and time to take effect when the CGI-SI baseline scores decreased by more than 1 point.MAIN OUTCOME MEASURES: The severity of mental disorder and amelioration were observed.RESULTS: ① The scores of CGI-SI after treatment were significantly decreased in the olanzapine group, haloperidol group and control group, and there were significant differences (P ＜ 0.01). ② The rates of marked effect in the three groups were 82.4%, 87.5% and 31.0%, respectively, and those in the two treatment groups were significantly different from that in the control group (P ＜ 0.01). ③ Both olanzapine and haloperidol began to take effect at small dosages, and it was the fasted in the olanzapine group, followed by the haloperidol group, and slowest in the control group.CONCLUSION: Olanzapine and haloperidol have similar effects in treating senile delirium. However, olanzapine is faster to take effect than haloperidol.

Contrast Research of Olanzapine and Risperidone in the Treatment of Senile Dementia of Behavioral and Psychological Symptoms

A controlled trial of olanzapine and fluoxetine in treatment of negative symptoms of schizophrenia

Comparative efficacy and safety of olanzapine and risperidone in the treatment of psychiatric and behavioral symptoms of Alzheimer's disease: Systematic review and meta-analysis

A double blinded multicenter clinical trial for evaluating the efficacy and safety of aripiprazole and risperidone in the treatment of schizophrenia

Efficacy and Safety of Long-Acting Risperidone on Early Onset Schizophrenia in Adolescent Patients

Olanzapine and Haloperidol for Senile Delirium: A Randomized Controlled Observation

Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia

Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia A Randomized, Double-Blind, Multicenter Study

Clinical evaluation of management of acute delirium after brain trauma with olanzapine

Risperidone Versus Haloperidol in the Treatment of Acute Exacerbations of Chronic Inpatients with Schizophrenia: a Randomized Double-Blind Study

The Efficacy and Adverse Effects of Haloperidol and Olanzapine: a Randomized Controlled Study.

Double-blind Comparison of Ziprasidone and Risperidone in the Treatment of Chinese Patients with Acute Exacerbation of Schizophrenia

One year follow-up study of olanzapine and risperidone in the treatment of patients with first-episode schizophrenia

Clinical Study of Risperidone Orally Disintegrating Tabiets and Clozapine in the Treatment of Schizophrenia

A Randomized,open Label and Parallel-Control Study for the Treatment of Refractory Schizophrenia with Risperidone and Clozapine

Retraction Note: Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis

Comparative Study Between Risperidone and Perphenazine in the Treatment of Female Patients with Schizophrenia

An Open-Label Randomised Comparison of Aripiprazole, Olanzapine and Risperidone for the Acute Treatment of First-Episode Schizophrenia: Eight-week Outcomes.

Effectiveness and Safety of Olanzapine in the Treatment of Schizophrenia among Asian Patients Switching from Conventional Antipsychotics

RETRACTED ARTICLE: Efficacy and Safety of Atypical Antipsychotic Drug Treatment for Dementia: a Systematic Review and Meta-Analysis

Randomized Double-Blind Control Study of Olanzapine Augmented with Fluoxetine for Schizophrenia with Depression Symptom